Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Livmarli
Maralixibat is a minimally absorbed, ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of chronic idiopathic constipation in adults and for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older. It belongs to the class of drugs known as bile acid sequestrants and works by inhibiting the reabsorption of bile acids in the ileum, increasing bile acid excretion in the feces and reducing bile acid levels in the liver.
Maralixibat is used to treat chronic idiopathic constipation in adults and cholestatic pruritus in patients with Alagille syndrome.
Outcome:
Increased bleeding risk
Mechanism:
Altered vitamin K absorption
Outcome:
Reduced absorption of both drugs
Mechanism:
Binding interaction
Outcome:
Potentially reduced efficacy of atorvastatin
Mechanism:
Decreased absorption
Most likely new formulation: Modified-release formulation for once-daily dosing (Year 2026, 60% confidence)
Based on usage patterns and clinical trial data, there is a 70% likelihood that maralixibat will maintain its current approved indications over the next 5 years.
IBAT Inhibitor, Bile Acid Sequestrant
Isothiazolidinone